// App-Quantinova.ai

1042 : Long-term Safety of Ixekizumab in Adult Patients with Psoriasis, Psoriatic Arthritis, and Axial Spondyloarthritis

Researchers

Presenter

  • Atul Deodhar

Principal Investigators

  • Andrew Blauvelt

  • Sergio Schwartzman

  • Carlo Salvarani

  • Meghan Feely

  • Andris Kronbergs

  • Nadia Eberhart

  • Danting Zhu

  • Elsa Mevel

  • Thorsten Holzkämper

  • Eswar Krishnan

  • Mark Lebwohl

  • Proton Rahman

  • Helena Marzo-Ortega

Medical Centers

  • Oregon Health & Science University, Portland, OR, USA, Portland, OR

  • Oregon Medical Research Center, Portland, OR, USA, Portland, OR

  • 72nd Street Medical Associates, Scarsdale, NY

  • University of Reggio Emilia, Reggio Emilia, Italy

  • Eli Lilly and Company, Indianapolis, IN

  • Eli Lilly & Company, Vienna, Austria

  • Eli Lilly and Company, Carmel, IN

  • Icahn School of Medicine at Mount Sinai, New York, NY

  • Memorial University, St. John's, NF, Canada

  • NIHR, Leeds Teaching Hospitals Trust and LIRMM, University of Leeds, Leeds, United Kingdom

Locations

  • United States

  • Italy

  • Austria

  • Canada

  • United Kingdom

Companies

  • Eli Lilly and Compan

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

  • Musculoskeletal

Disease

  • Axial spondyloarthritis

  • Psoriatic arthritis

  • Spondyloarthritis

  • Psoriasis

Biomarkers

  • N/A

Drug/Treatment

  • LY2439821

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved